atorvastatin has been researched along with Paralysis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bravo, M; Hur, EM; Mitchell, DJ; Patarroyo, JC; Radosevich, JL; Ruiz, PJ; Sobel, RA; Steinman, L; Stüve, O; Youssef, S; Zamvil, SS | 1 |
| Aktas, O; Brocke, S; Dorr, J; Endres, M; Nitsch, R; Prozorovski, T; Sallach, S; Seeger, B; Smorodchenko, A; Waiczies, S; Zipp, F | 1 |
| Barbosa, E; Christie, DK; Pannu, R; Singh, AK; Singh, I | 1 |
3 other study(ies) available for atorvastatin and Paralysis
| Article | Year |
|---|---|
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Topics: Adoptive Transfer; Amino Acid Sequence; Animals; Antigen-Presenting Cells; Atorvastatin; Cell Division; Central Nervous System Diseases; Cytokines; DNA-Binding Proteins; Encephalomyelitis, Autoimmune, Experimental; Female; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Microglia; Molecular Sequence Data; Multiple Sclerosis; Nuclear Proteins; Paralysis; Phosphorylation; Pyrroles; RNA, Messenger; STAT4 Transcription Factor; STAT6 Transcription Factor; Th2 Cells; Trans-Activators | 2002 |
Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin.
Topics: Animals; Apoptosis; Atorvastatin; CD4-Positive T-Lymphocytes; Cell Cycle; Cell Division; Cell Line; Encephalomyelitis, Autoimmune, Experimental; Female; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Mice; Mice, Inbred Strains; Myelin Proteolipid Protein; Paralysis; Peptide Fragments; Pyrroles; Recurrence; Spinal Cord; Th1 Cells | 2003 |
Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury.
Topics: Animals; Atorvastatin; Blood-Brain Barrier; Chemotaxis, Leukocyte; Cytokines; Down-Regulation; Endothelial Cells; Female; Gait Disorders, Neurologic; Heptanoic Acids; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Neuroprotective Agents; Paralysis; Pyrroles; Rats; Rats, Sprague-Dawley; Recovery of Function; Regional Blood Flow; rhoA GTP-Binding Protein; Spinal Cord; Spinal Cord Injuries; Terpenes; Treatment Outcome | 2007 |